The British Journal of Rheumatology, Vol 37, 39-45, Copyright © 1998 by British Society for Rheumatology
S Jacobsen, P Halberg, S Ullman, WJ Van Venrooij, M Hoier-Madsen, A Wiik and J Petersen
The objective was to investigate the relationship between the presence of
different types of antinuclear antibodies (ANA) in patients with systemic
sclerosis (SSc) and the presence of clinical features. Sera from 230
patients with SSc were tested for the presence of ANA, including
anticentromere antibodies (ab), antitopoisomerase I ab, anti- U1 RNP ab and
antinucleolar ab, including anti-Th RNP, anti-U3 RNP and anti-U17 RNP.
Clinical features were registered prospectively in a clinical database.
Eighty-two per cent of the patients were women. The median age was 58 yr
(45-67, quartiles) and median age at disease onset was 44 (30-55) yr. ANA
were found in 86% of the patients (anticentromere: 34%; antitopoisomerase
I: 14%; anti-U1 RNP: 6.5%; antinucleolar total: 16%; anti-Th RNP: 2.2%;
anti-U3 RNP: 3.5%; anti- U17 RNP: 0%). Anticentromere ab were found to be
related to a high prevalence of calcinosis, telangiectasia, digital ulcers,
acrosclerosis, primary biliary cirrhosis, isolated reduction of pulmonary
diffusing capacity, and a low prevalence of radiological evidence of
pulmonary fibrosis. Antitopoisomerase I ab were associated with a high
prevalence of digital joint deformity, distal osteolysis, radiological
signs of pulmonary fibrosis, a low prevalence of calcinosis and late onset
of disease. Anti-U1 RNP ab were related to a high prevalence of arthritis
and myositis, a low prevalence of calcinosis, and early disease onset. The
presence of antinucleolar ab, including anti-U3 RNP and anti-Th RNP, was
not significantly related to any particular clinical features in this
study; possibly due to the small number of patients with these ab. The
presence of anticentromere, antitopoisomerase I and anti-U1 RNP ab in the
serum was also found to have previously described clinical correlations in
a group of Danish SSc patients.
ORIGINAL PAPERS
Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis
Department of Rheumatology, Copenhagen University Hospital at Hvidovre, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Hesselstrand, A. Scheja, G. Q. Shen, A. Wiik, and A. Akesson The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis Rheumatology, April 1, 2003; 42(4): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Benitha, M. Modi, and M. Tikly Osteolysis of the cervical spine and mandible in systemic sclerosis: a case report with computed tomography and magnetic resonance imaging findings Rheumatology, October 1, 2002; 41(10): 1198 - 1200. [Full Text] [PDF]
|
|
|
|
 |
|
 T Dick, R Mierau, P Bartz-Bazzanella, M Alavi, M Stoyanova-Scholz, J Kindler, and E Genth Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis Ann Rheum Dis, February 1, 2002; 61(2): 121 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Della Rossa, G Valentini, S Bombardieri, W Bencivelli, A J Silman, S D'Angelo, M M. Cerinic, J F Belch, C M Black, R Becvar, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres Ann Rheum Dis, June 1, 2001; 60(6): 585 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sleeping eyes Postgrad. Med. J., May 1, 2000; 76(895): 311a - 311. [Full Text]
|
|
|
|
|
|
B. Rozman, and T. Kveder Re: Tager and Tikly. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans Rheumatology, February 1, 2000; 39(2): 220 - 221. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kern, M. Kron, and K. Hiesche Measurement of Antinuclear Antibodies: Assessment of Different Test Systems Clin. Vaccine Immunol., January 1, 2000; 7(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|